Eisai Co., Ltd.
https://www.eisai.com/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eisai Co., Ltd.
Medtech Investors Gain When The Compass Points To Patients
Seasoned business developer and investor Oern Stuge has worked with the very biggest in medtech in a career spanning over three decades. He bemoans the harm that European policymakers are doing to the one-time capital of the world of medtech innovation. But on the other hand, he knows that the best ideas have a habit of succeeding, regardless of geography.
Stock Watch: All Roads Lead Back To Pricing In Biogen And J&J’s Third-Quarter Earnings
Johnson & Johnson’s divisional recoveries were in contrast to the declines of Biogen’s franchises but both companies had a competitive pressure and a drug pricing issue.
Biogen’s Q3 Aduhelm Sales Even Worse Than Expected
Analysts expected at least $12m in third quarter sales, but the Alzheimer’s therapy brought in just $300,000. The company says educating doctors and procuring a coverage determination from CMS – not lower pricing – are key to growth.
Potential For Califf’s Second Term As US FDA Commissioner Surprises, Excites Stakeholders
Many supporters believe Robert Califf checks all the boxes, but if nominated he would also face many familiar confirmation challenges.
Company Information
- Industry
- Distributors
- Pharmaceuticals
- Other Names / Subsidiaries
-
- EA Pharma Co., Ltd.
- Eisai China Inc
- Eisai Laboratorios
- Eisai Mexico
- Eisai Participacoes Ltda. (Brazil Subsidiary)
- H3 Biomedicine
- HI-Eisai Pharmaceutical Inc.
- Jingyi Weixiang (Shanghai) Health Industry Development Limited
- Liaoning TianYi Biological Pharmaceutical Co., Ltd.
- KAN Research Institute, Inc.
- MGI Pharma, Inc.
- Morphotek, Inc.
- Zycos Inc.
- Eisai Vietnam Co., Ltd.